10x Genomics (TXG) awards 8,829 RSUs to company director
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Teichmann Sarah A. reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics director Sarah A. Teichmann received an equity award of 8,829 restricted stock units (RSUs) of Class A Common Stock. The award was granted at no cash cost per share and increased her direct holdings to 35,609 shares.
Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. One quarter of the RSUs will vest on each quarterly anniversary starting from May 21, 2026, as long as she continues as a service provider through each vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Teichmann Sarah A.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 8,829 | $0.00 | -- |
Holdings After Transaction:
Class A Common Stock — 35,609 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
RSU grant size: 8,829 RSUs
Post-grant holdings: 35,609 shares
Grant price: $0.0000 per share
+2 more
5 metrics
RSU grant size
8,829 RSUs
Grant of Class A Common Stock RSUs to director
Post-grant holdings
35,609 shares
Total Class A Common Stock directly held after transaction
Grant price
$0.0000 per share
RSUs awarded at no cash cost per share
Vesting start reference date
May 21, 2026
Quarterly vesting anniversaries measured from this date
Vesting pattern
1/4 each quarter
One quarter of RSUs vest on each quarterly anniversary
Key Terms
restricted stock units ("RSUs"), contingent right, service provider
3 terms
restricted stock units ("RSUs") financial
"Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents a contingent right to receive one share of Class A Common Stock..."
service provider financial
"...subject to the Reporting Person continuing as a service provider through each such date."
FAQ
What insider transaction did 10x Genomics (TXG) report for Sarah A. Teichmann?
10x Genomics reported that director Sarah A. Teichmann received a grant of 8,829 restricted stock units of Class A Common Stock. These RSUs are part of her equity compensation and convert into shares only as they vest over time.
Are the 8,829 RSUs for 10x Genomics (TXG) an open-market purchase or sale?
The 8,829 RSUs represent a grant, not an open-market purchase or sale. They are compensation-related restricted stock units awarded at no cash price, which will convert into Class A shares only as they vest according to the disclosed schedule.
What is the vesting schedule for Sarah A. Teichmann’s 8,829 RSUs in 10x Genomics (TXG)?
The 8,829 RSUs vest in four equal installments. One quarter of the RSUs will vest on each quarterly anniversary measured from May 21, 2026, provided Sarah A. Teichmann continues as a service provider through each corresponding vesting date.
What does each RSU granted to Sarah A. Teichmann by 10x Genomics (TXG) represent?
Each RSU represents a contingent right to receive one share of 10x Genomics Class A Common Stock. She receives actual shares only when RSUs vest, assuming she continues her service, aligning part of her compensation with long-term shareholder interests.